Replies to post #1516 on Pozen Inc. (POZN)

[Fastmandoo]

Current report filing (8-K)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 30, 2010

POZEN INC.

(Exact Name of Registrant as Specified in Charter)


Delaware 000-31719 62-1657552
(State or Other Jurisdiction
of Incorporation) (Commission File Number) (IRS Employer Identification No.)


1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
27517
(Address of Principal Executive Offices) (Zip Code)





[phone]
(Registrant's telephone number, including area code)





Not applicable
(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).




--------------------------------------------------------------------------------





Item 8.01. Other Events.

On April 30, 2010, POZEN Inc. and AstraZeneca AB, issued a press release to announce that the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcers . The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release of POZEN Inc. dated April 30, 2010.





- 2 -
--------------------------------------------------------------------------------





SIGNATURES




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

POZEN INC.


By: /s/ William L. Hodges
Name: William L. Hodges
Title: Chief Financial Officer







Date: May 3, 2010